Differential effects of membrane and soluble Fas ligand on cardiomyocytes: Role in ischemia/reperfusion injury

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 7, 2003, Pages 811-821

  Date, Taro ^a   Mochizuki, Seibu ^b   Belanger, Adam J ^a   Yamakawa, Midori ^a   Luo, Zhengyu ^a   Vincent, Karen A ^a   Cheng, Seng H ^a   Gregory, Richard J ^a   Jiang, Canwen ^a  

^a GENZYME CORPORATION   (United States)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Caspase; Fas ligand; Ischemia reperfusion; Mitochondrial damage

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 8; CASPASE 9; FAS LIGAND;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; MITOCHONDRIAL MEMBRANE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; REDUCTION; REOXYGENATION; SIGNAL TRANSDUCTION; VIRUS SHEDDING;

EID: 0038799913     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2828(03)00139-1     Document Type: Article

References (47)

1. Nagata S. Fas ligand-induced apoptosis. Ann Rev Genet. 33:1999;29-55.
2. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:1998;491-501.
3. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1998;1675-1687.
4. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
5. Wang X. The expanding role of mitochondria in apoptosis. Gene Dev. 15:2001;2922-2933.
6. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat M. 4:1998;31-36.
7. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., et al. Conversion of membrane Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp M. 187:1998;1205-1213.
8. Hohlbaum A.M., Moe S., Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp M. 191:2000;1209-1220.
9. Brunner T., Mogil R.J., LaFace D., Yoo N.J., Mahboubi A., Echeverri F., et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:1995;441-444.
10. Dhein J., Walczak H., Baumler C., Debatin K.M., Krammer P.H. Autocrine T-cell suicide mediated by APO-1/FasL. Nature. 373:1995;438-441.
11. Ju S.T., Panka D.J., Cui H., Ettinger R., el-Khatib M., Sherr D.H., et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373:1995;444-448.
12. Belanger A.J., Scaria A., Lu H., Sullivan J.A., Cheng S.H., Gregory R.J., et al. Fas ligand/Fas-mediated apoptosis in human coronary artery smooth muscle cells: therapeutic implications of fratricidal mode of action. Cardiovasc Res. 51:2001;749-761.
13. Luo Z., Garron T., Palasis M., Lu H., Belanger A.J., Scaria A., et al. Enhancement of Fas ligand-induced inhibition of neointimal formation in rabbit femoral and iliac arteries by coexpression of p35. Hum Gene Ther. 12:2001;2191-2202.
14. Wajant H. The Fas signaling pathway: more than a paradigm. Science. 296:2002;1635-1636.
15. Felzen B., Shilkrut M., Less H., Sarapov I., Maor G., Coleman R., et al. Fas (CD95/Apo-1)-mediated damage to ventricular myocytes by cytotoxic T lymphocytes from perforin-deficient mice: a major role for inositol 1,4,5-trisphosphate. Circ Res. 82:1998;438-450.
16. Shilkrut M., Gealekman O., Rosen D., Berke G., Woodcock E., Binah O. Electrophysiologic perturbations and arrhythmogenic activity caused by activation of the Fas receptor in murine ventricular myocytes: role of the inositol trisphosphate pathway. J Cardiovasc Electrophysiol. 12:2001;185-195.
17. Kang P.M., Haunstetter A., Aoki H., Usheva A., Izumo S. Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. Circ Res. 87:2000;118-125.
18. Jeremias I., Kupatt C., Martin-Villalba A., Habazettl H., Schenkel J., Boekstegers P., et al. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation. 102:2000;915-920.
19. Nelson D.P., Setser E., Hall D.G., Schwartz S.M., Hewitt T., Klevitsky R., et al. Proinflammatory consequences of transgenic fas ligand expression in the heart. J Clin Invest. 105:2000;1199-1208.
20. Wollert K.C., Heineke J., Westermann J., Ludde M., Fiedler B., Zierhut W., et al. The cardiac Fas (APO-1/CD95) Receptor/Fas ligand system: relation to diastolic wall stress in volume-overload hypertrophy in vivo and activation of the transcription factor AP-1 in cardiac myocytes. Circulation. 101:2000;1172-1178.
21. Tanaka M., Ito H., Adachi S., Akimoto H., Nishikawa T., Kasajima T., et al. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res. 75:1994;426-433.
22. Fliss H., Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res. 79:1996;949-956.
23. Long X., Boluyt M.O., Hipolito M.L., Lundberg M.S., Zheng J.S., O'Neill L., et al. p53 and the hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes. J Clin Invest. 99:1997;2635-2643.
24. Bialik S., Cryns V.L., Drincic A., Miyata S., Wollowick A.L., Srinivasan A., et al. The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res. 85:1999;403-414.
25. Stephanou A., Scarabelli T.M., Brar B.K., Nakanishi Y., Matsumura M., Knight R.A., et al. Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701. J Biol Chem. 276:2001;28340-28347.
26. Scarabelli T.M., Stephanou A., Pasini E., Comini L., Raddino R., Knight R.A., et al. Different signaling pathways induce apoptosis in endothelial cells and cardiac myocytes during ischemia/reperfusion injury. Circ Res. 90:2002;745-748.
27. Yaniv G., Shilkrut M., Lotan R., Berke G., Larisch S., Binah O. Hypoxia predisposes neonatal rat ventricular myocytes to apoptosis induced by activation of the Fas (CD95/Apo-1) receptor: Fas activation and apoptosis in hypoxic myocytes. Cardiovasc Res. 54:2002;611-623.
28. Date T., Belanger A.J., Mochizuki S., Sullivan J.A., Liu L.X., Scaria A., et al. Adenovirus-mediated expression of p35 prevents hypoxia/reoxygenation injury by reducing reactive oxygen species and caspase activity. Cardiovasc Res. 55:2002;309-319.
29. Clem R.J., Fechheimer M., Miller L.K. Prevention of apoptosis by a baculovirus gene during infection of insect cells. Science. 254:1991;1388-1390.
30. Belanger A.J., Lu H., Date T., Liu L.X., Vincent K.A., Akita G.Y., et al. Hypoxia up-regulates expression of peroxisome proliferator-activated receptor gamma angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor 1alpha. J Mol Cell Cardiol. 34:2002;765-774.
31. Webster K.A., Discher D.J., Kaiser S., Hernandez O., Sato B., Bishopric N.H. Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a pH shift and is independent of p53. J Clin Invest. 104:1999;239-252.
32. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J M. 334:1996;1717-1725.
33. Perez C., Albert I., DeFay K., Zachariades N., Gooding L., Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell. 63:1990;251-258.
34. Hayakawa K., Takemura G., Koda M., Kawase Y., Maruyama R., Li Y., et al. Sensitivity to apoptosis signal, clearance rate, and ultrastructure of fas ligand-induced apoptosis in in vivo adult cardiac cells. Circulation. 105:2002;3039-3045.
35. Koseki T., Inohara N., Chen S., Nunez G. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc Natl Acad Sci USA. 95:1998;5156-5160.
36. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., et al. Inhibition of death receptor signals by cellular FLIP. Nature. 388:1997;190-195.
37. Yang X., Khosravi-Far R., Chang H.Y., Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 89:1997;1067-1076.
38. Ichijo H., Nishida E., Irie K., ten Dijke P., Saitoh M., Moriguchi T., et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 275:1997;90-94.
39. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 391:1998;43-50.
40. de Moissac D., Gurevich R.M., Zheng H., Singal P.K., Kirshenbaum L.A. Caspase activation and mitochondrial cytochrome c release during hypoxia-mediated apoptosis of adult ventricular myocytes. J Mol Cell Cardiol. 32:2000;53-63.
41. Suzuki K., Kostin S., Person V., Elsasser A., Schaper J. Time course of the apoptotic cascade and effects of caspase inhibitors in adult rat ventricular cardiomyocytes. J Mol Cell Cardiol. 33:2001;983-994.
42. Aoyama T., Takemura G., Maruyama R., Kosai K., Takahashi T., Koda M., et al. Molecular mechanisms of non-apoptosis by Fas stimulation alone versus apoptosis with an additional actinomycin D in cultured cardiomyocytes. Cardiovasc Res. 55:2002;787-798.
43. Binah O. Immune effector mechanisms in myocardial pathologies. Int J Mol M. 6:2000;3-16.
44. Yamaguchi S., Yamaoka M., Okuyama M., Nitoube J., Fukui A., Shirakabe M., et al. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am J Cardiol. 83:1999;1500-1503.
45. Araki T., Shibata M., Takano R., Hisahara S., Imamura S.I., Fukuuchi Y., et al. Conditional expression of anti-apoptotic protein p35 by Cre-mediated DNA recombination in cardiomyocytes from loxP-p35-transgenic mice. Cell Death Differ. 7:2000;485-492.
46. Haunstetter A., Izumo S. Toward anti-apoptosis as a new treatment modality. Circ Res. 86:2000;371-376.
47. Laugwitz K.L., Moretti A., Weig H.J., Gillitzer A., Pinkernell K., Ott T., et al. Blocking caspase-activated apoptosis improves contractility in failing myocardium. Human Gene Ther. 12:2001;2051-2063.